Correlation of Suppression by Cytosine Arabinoside (Ara-C) of Thymidine Incorporation into Leukemic Cells and Clinical Response to Low Dose Ara-C
スポンサーリンク
概要
- 論文の詳細を見る
Cytosine arabinoside (Ara-C) is the major drug in the treatment of acute nonlymphocytic leukemia, but human leukemic cells are heterogenous with respect to their response to the drug. We measured <I>in vitro</I> suppression by Ara-C of <SUP>3</SUP>H-thymidine incorporation into leikemic cells which were obtained from children with relapsed or induction-failure acute leukemia. Leukemic cells (1-2 × 10<SUP>5</SUP>) suspended in RPMI 1640 with 25 mm Hepes buffer and 30% patient's serum were placed in wells of microtiter plates with Ara-C at final concentration of 30 ng/ml. After 5 and 24 hours of incubation, 0.2 μCi of <SUP>3</SUP>H-thymidine were added to each well and, after a 3-hour labelling period, counts of <SUP>3</SUP>H-thymidine uptake were made on aliquots of cells drawn from the well with an automated cell harvester. In the leukemic cells of 3 children who achieved complete remission by low dose Ara-C therapy, the degree of suppression of <SUP>3</SUP>H-thymidine incorporation at 5 hours after incubation with Ara-C remained until 24 hours. In contrast, the patients whose cells showed the recovery <SUP>3</SUP>H -thymidine uptake at 24 hours, though revealing the the suppression at 5 hours, did not achieve remission.
- 特定非営利活動法人 日本小児血液・がん学会の論文
特定非営利活動法人 日本小児血液・がん学会 | 論文
- The Parent's Emotional Adaptation to the Children's Malignant Disease
- Side Effect of Cranial Radiation in Childhood Acute Leukemia
- Red Blood Cell Volume Distribution Width in Normal Children and in the Patients with Various Kinds of Hematological Disorders.
- Effective Conditioning of Donors for Granulocyte Transfusions with Recombinant Human Granulocyte Colony-Stimulating Factor.
- Two Infant Girls of CNS Leukemia with Chronic Subdural Hematoma